Dr. Maragakis on Q Therapeutics’ FDA Clearance for Clinical Trials with Q-Cells in Patients with ALS
Dr. Nicholas Maragakis, professor at Johns Hopkins University School of Medicine and NEALS member, was a key contributor to the pre-clinical development of Q-Cells. Read what he has to say about this research opportunity.
Q Therapeutics announced clearance of its investigational new drug application for phase 1/2a clinical trials with Q-Cells in patients with ALS on June 4, 2015.
Dr. Nicholas Maragakis, professor at Johns Hopkins University School of Medicine and NEALS member, was a key contributor to the pre-clinical development of Q-Cells.
“This has been an amazing opportunity to be a part of the pre-clinical research that has brought Q Therapeutics and their product, Q-Cells, to this point. Our partnership has spanned several years and has included the demonstration that glial cells like astrocytes and oligodendrocytes play a role not only in ALS disease progression but also potentially in motor neuron protection. The IND approval that was obtained by Q Therapeutics, Inc. represents efforts from a number of different funding partnerships representing the ALS community as well as input from basic scientists and clinicians associated with the Northeast ALS Consortium. What is really exciting is the opportunity to bring this as a potential therapeutic to our patients with ALS. I’m looking forward to the next chapter,“ Dr. Maragakis said of this research development.
Download press release here.